Derm Fall Clinical

This interview following Fall Clinical highlights new phase 3 data on patient-reported outcomes from the ARRECTOR study evaluating roflumilast foam for psoriasis.

This conference review highlights several of the most notable stories and recent data covered by HCPLive at the Fall Clinical Dermatology Conference.

This interview from Fall Clinical featured a discussion of new findings on upadacitinib (Rinvoq) for patients with atopic dermatitis.

These data suggest brodalumab’s safety profile is consistent with findings from long-term clinical trials, with no new occurrences of suicide and a low rate of fungal infection.

This interview at the Fall Clinical Dermatology Conference features a discussion with Stein Gold regarding the open-label extension of the phase 3 ADORING trial regarding tapinarof.

Many with moderate-to-severe atopic dermatitis do not reach treatment targets in 12 months, underscoring a need for proactive management strategies.

Stein Gold speaks in this interview about the new lebrikizumab (Ebglyss) data presented at the Fall Clinical Dermatology Conference.

Murina highlighted takeaways from her seminar-in-depth regarding the evolving therapeutic landscape of HS.

This discussion with Murina covers several tips for dermatologists to implement, 1 of which touched on omega-3 supplementation for ocular rosacea.

In her Fall Clinical interview, Murina highlighted several key takeaways related to her talk titled ‘Managing Psoriasis with Oral Therapy: 2024 & Beyond.’

This interview from Fall Clinical covers 2 additional tips for clinical practice as well as unmet needs among patients.

In this interview at Fall Clinical Dermatology, Ferris and Bhatia highlighted several elements of skin cancer detection and management as well as unmet needs of patients.

This Fall Clinical Dermatology Conference interview with Song features a discussion regarding several useful clinical pearls for dermatologists.

This interview features a discussion with Bhatia and Ferris regarding the necessity of collaboration between dermatologists and oncologists for skin cancer.

In this interview, Neal Bhatia, MD, and Laura Korb Ferris, MD, PhD, spoke on their Fall Clinical Conference talk titled ‘Beyond the Biopsy: Other Methods To Help Us Manage Skin Cancer.’

This interview with Bunick highlighted the LEVEL UP phase 3b/4 trial findings regarding upadacitinib treatment of patients with atopic dermatitis.

These findings from the phase 3 STRATUM trial suggest significant DLQI score improvements as early as the second week of treatment with roflumilast foam.

In this interview, Bunick spoke about the contents of his Fall Clinical Dermatology presentation specifically regarding mechanisms of action and safety of systemic therapies.

In these data presented at the Fall Clinical Dermatology conference, population-based data on utilization and duration of systemic corticosteroid exposure was highlighted.

In this interview, Kwatra highlighted several key takeaways from his talks on prurigo nodularis, atopic dermatitis, and itch at the Fall Clinical Dermatology Conference.

These long-term extension trial data from ADORING 3 highlight tapinarof cream’s efficacy in adults and children aged 2 years and older with atopic dermatitis.

In this interview segment, Del Rosso highlighted his Fall Clinical presentation takeaways covered in the talk ‘What’s New in the Medicine Chest - Part 2.’

These data from the ADapt study, presented at Fall Clinical, suggest improvements among patients with eczema given lebrikizumab-lbkz who had been previously treated with dupilumab.

These data were presented at Fall Clinical, highlighting the reductions in Eczema Area and Severity Index scores and the overall long-term safety profile of tralokinumab-ldrm.

These data demonstrated guselkumab’s success for the majority of patients with low body surface area (BSA) moderate plaque psoriasis and special site involvement.

This talk was titled ‘Heard About It, Did It, Now it's Part of My Practice,’ during which Swanson highlighted creative options for conditions such as guttate psoriasis and pyogenic granulomas.

In the first part of his Fall Clinical presentation on new topical medications, Del Rosso discusses new therapies available for use among dermatologists.

At the Fall Clinical Dermatology conference, Chovatiya presented on chronic hand eczema and facts about its pathophysiology, diagnosis, and management.

In this interview with Chovatiya, he highlights some of the elements of the presentations being given at the Fall Clinical Dermatology conference in Las Vegas.

This overview highlights our upcoming conference coverage at the Fall Clinical Dermatology Conference in Las Vegas.